RU2018129775A3 - - Google Patents

Download PDF

Info

Publication number
RU2018129775A3
RU2018129775A3 RU2018129775A RU2018129775A RU2018129775A3 RU 2018129775 A3 RU2018129775 A3 RU 2018129775A3 RU 2018129775 A RU2018129775 A RU 2018129775A RU 2018129775 A RU2018129775 A RU 2018129775A RU 2018129775 A3 RU2018129775 A3 RU 2018129775A3
Authority
RU
Russia
Application number
RU2018129775A
Other versions
RU2744432C2 (ru
RU2018129775A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018129775A publication Critical patent/RU2018129775A/ru
Publication of RU2018129775A3 publication Critical patent/RU2018129775A3/ru
Application granted granted Critical
Publication of RU2744432C2 publication Critical patent/RU2744432C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2018129775A 2016-02-19 2017-02-17 Фармацевтическая композиция, включающая ингибитор янус-киназы или его фармацевтически приемлемую соль RU2744432C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610094168 2016-02-19
CN201610094168.2 2016-02-19
PCT/CN2017/073869 WO2017140254A1 (zh) 2016-02-19 2017-02-17 一种含有jak激酶抑制剂或其可药用盐的药物组合物

Publications (3)

Publication Number Publication Date
RU2018129775A RU2018129775A (ru) 2020-03-19
RU2018129775A3 true RU2018129775A3 (ru) 2020-05-25
RU2744432C2 RU2744432C2 (ru) 2021-03-09

Family

ID=59624719

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018129775A RU2744432C2 (ru) 2016-02-19 2017-02-17 Фармацевтическая композиция, включающая ингибитор янус-киназы или его фармацевтически приемлемую соль

Country Status (13)

Country Link
US (1) US10786507B2 (ru)
EP (1) EP3417861B1 (ru)
JP (1) JP6875407B2 (ru)
KR (1) KR20180109992A (ru)
CN (1) CN107530348B (ru)
AU (1) AU2017220971A1 (ru)
BR (1) BR112018015369A2 (ru)
CA (1) CA3014090A1 (ru)
HK (1) HK1244704A1 (ru)
MX (1) MX2018009741A (ru)
RU (1) RU2744432C2 (ru)
TW (1) TWI745349B (ru)
WO (1) WO2017140254A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3033827A1 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
WO2018133823A1 (zh) * 2017-01-20 2018-07-26 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法
CN111205290B (zh) * 2018-11-22 2021-10-08 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的结晶形式及其制备方法
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
TW202112376A (zh) * 2019-06-10 2021-04-01 英屬開曼群島商百濟神州有限公司 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021129600A1 (zh) * 2019-12-23 2021-07-01 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂药物组合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112023001283A2 (pt) 2020-07-28 2023-02-14 Arcutis Biotherapeutics Inc Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica
MX2023005763A (es) 2020-11-17 2023-05-29 Arcutis Biotherapeutics Inc Composiciones y metodos para la administracion dermica profunda de farmacos.
CN114591321A (zh) * 2020-12-04 2022-06-07 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途
CN113813228B (zh) * 2021-10-11 2023-04-18 北京鑫开元医药科技有限公司 一种具有jak激酶抑制活性的注射液及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
RS57621B1 (sr) * 2011-12-21 2018-11-30 Jiangsu Hengrui Medicine Co Derivat šestočlanog heteroaril prstena pirola, postupak njegove pripreme i njegova medicinska upotreba
US9422300B2 (en) 2013-06-07 2016-08-23 Jiangsu Hengrui Medicine Co., Ltd. Bisulfate of janus kinase (JAK) inhibitor and preparation method therefor
CN105566327A (zh) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
CA2965716C (en) 2014-11-05 2023-03-21 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof

Also Published As

Publication number Publication date
HK1244704A1 (zh) 2018-08-17
EP3417861A4 (en) 2019-09-18
CA3014090A1 (en) 2017-08-24
TWI745349B (zh) 2021-11-11
US20190030033A1 (en) 2019-01-31
TW201729812A (zh) 2017-09-01
EP3417861A1 (en) 2018-12-26
BR112018015369A2 (pt) 2018-12-18
KR20180109992A (ko) 2018-10-08
RU2744432C2 (ru) 2021-03-09
WO2017140254A1 (zh) 2017-08-24
US10786507B2 (en) 2020-09-29
CN107530348A (zh) 2018-01-02
JP2019505525A (ja) 2019-02-28
CN107530348B (zh) 2020-10-20
EP3417861B1 (en) 2020-09-23
RU2018129775A (ru) 2020-03-19
JP6875407B2 (ja) 2021-05-26
MX2018009741A (es) 2018-11-09
AU2017220971A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
BR112019003108A2 (ru)
RU2018129581A3 (ru)
RU2018129775A3 (ru)
RU2018135081A3 (ru)
RU2017127989A3 (ru)
BR212018070320U2 (ru)
BR112019009373A2 (ru)
BR212019008871U2 (ru)
JP1564560S (ru)
JP1569218S (ru)
JP1565073S (ru)
CN303622905S (ru)
CN303580172S (ru)
CN303543137S (ru)
CN303548773S (ru)
CN303551594S (ru)
CN303670504S (ru)
CN303552074S (ru)
CN303674786S (ru)
CN303616175S (ru)
CN303553673S (ru)
CN303640652S (ru)
CN303678400S (ru)
CN303675693S (ru)
CN303539643S (ru)